Polymeric nano- and microparticles for the oral delivery of peptides and peptidomimetics

被引:175
作者
Allémann, E [1 ]
Leroux, JC
Gurny, R
机构
[1] Univ Geneva, Sch Pharm, Geneva, Switzerland
[2] Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada
关键词
nanoparticles; microparticles; peptides; peptidomimetics; oral administration; in vivo studies;
D O I
10.1016/S0169-409X(98)00039-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Due to recent advances, numerous bioactive peptides are now available in large quantities. Administering these substances by the oral route appears as a formidable challenge due to their insufficient stability in the gastrointestinal tract and their poor absorption pattern. Several approaches have been investigated to improve their oral bioavailability. Among them, the use of polymeric particulate delivery systems (microparticles and nanoparticles) represents a promising concept. Encapsulating or incorporating peptides in particles should at least protect these substances against degradation and, in some cases, also enhance their absorption. The aim of this paper is to review the principal studies where peptide-loaded particles were administered by the oral route. The preparation methods and in vitro trials are presented and in vivo results are discussed with emphasis placed on the peptide blood levels reached or on the biological effects observed. Whether or not intact particles can be taken up and translocated to the systemic circulation is not the aim of this review. (C) 1998 Published by Elsevier Science B.V. All rights reserved.
引用
收藏
页码:171 / 189
页数:19
相关论文
共 66 条
[1]   AN ORALLY BIOAVAILABLE HIV-1 PROTEASE INHIBITOR CONTAINING AN IMIDAZOLE-DERIVED PEPTIDE-BOND REPLACEMENT - CRYSTALLOGRAPHIC AND PHARMACOKINETIC ANALYSIS [J].
ABDELMEGUID, SS ;
METCALF, BW ;
CARR, TJ ;
DEMARSH, P ;
DESJARLAIS, RL ;
FISHER, S ;
GREEN, DW ;
IVANOFF, L ;
LAMBERT, DM ;
MURTHY, KHM ;
PETTEWAY, SR ;
PITTS, WJ ;
TOMASZEK, TA ;
WINBORNE, E ;
ZHAO, BG ;
DREYER, GB ;
MEEK, TD .
BIOCHEMISTRY, 1994, 33 (39) :11671-11677
[2]  
ALKHOURI N, 1986, PHARM ACTA HELV, V61, P274
[3]   IN-VITRO EXTENDED-RELEASE PROPERTIES OF DRUG-LOADED POLY(DL-LACTIC ACID) NANOPARTICLES PRODUCED BY A SALTING-OUT PROCEDURE [J].
ALLEMANN, E ;
LEROUX, JC ;
GURNY, R ;
DOELKER, E .
PHARMACEUTICAL RESEARCH, 1993, 10 (12) :1732-1737
[4]  
ALLEMANN E, 1993, EUR J PHARM BIOPHARM, V39, P173
[5]   CGP-53437, AN ORALLY BIOAVAILABLE INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROTEASE WITH POTENT ANTIVIRAL ACTIVITY [J].
ALTERI, E ;
BOLD, G ;
COZENS, R ;
FAESSLER, A ;
KLIMKAIT, T ;
LANG, M ;
LAZDINS, J ;
PONCIONI, B ;
ROESEL, JL ;
SCHNEIDER, P ;
WALKER, M ;
WOODSCOOK, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (10) :2087-2092
[6]  
[Anonymous], [No title captured]
[7]  
Banga AK, 1995, THERAPEUTIC PEPTIDES
[8]   ANTIMETASTATIC ACTIVITY OF MDP-L-ALANYL-CHOLESTEROL INCORPORATED INTO VARIOUS TYPES OF NANOCAPSULES [J].
BARRATT, G ;
PUISIEUX, F ;
YU, WP ;
FOUCHER, C ;
FESSI, H ;
DEVISSAGUET, JP .
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1994, 16 (5-6) :457-461
[9]   Protease inhibitors in patients with HIV disease - Clinically important pharmacokinetic considerations [J].
Barry, M ;
Gibbons, S ;
Back, D ;
Mulcahy, F .
CLINICAL PHARMACOKINETICS, 1997, 32 (03) :194-209
[10]  
BECK PH, 1994, EUR J PHARM BIOPHARM, V40, P134